Julian Symons
Chief Tech/Sci/R&D Officer presso ALIGOS THERAPEUTICS, INC.
Patrimonio netto: 322 344 $ in data 30/04/2024
Profilo
Julian A.
Symons is currently the Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. Prior to this, he worked as the Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Dr. Symons holds a doctorate degree from York University and an undergraduate degree from the University of Central Lancashire.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 01/03/2024 | 394 064 ( 0.54% ) | 322 344 $ | 30/04/2024 |
Posizioni attive di Julian Symons
| Società | Posizione | Inizio |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Precedenti posizioni note di Julian Symons
| Società | Posizione | Fine |
|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/04/2018 |
Formazione di Julian Symons
| York University | Doctorate Degree |
| University of Central Lancashire | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Julian Symons
